These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36914565)

  • 1. An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications.
    Shih LJ; Yang CC; Liao MT; Lu KC; Hu WC; Lin CP
    Virulence; 2023 Dec; 14(1):2190650. PubMed ID: 36914565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial.
    Sheehan JR; Calpin P; Kernan M; Kelly C; Casey S; Murphy D; Alvarez-Iglesias A; Giacomini C; Cody C; Curley G; McGeary S; Hanley C; McNicholas B; van Haren F; Laffey JG; Cosgrave D
    Trials; 2022 Sep; 23(1):774. PubMed ID: 36104785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
    Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
    Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 infection: an overview on cytokine storm and related interventions.
    Montazersaheb S; Hosseiniyan Khatibi SM; Hejazi MS; Tarhriz V; Farjami A; Ghasemian Sorbeni F; Farahzadi R; Ghasemnejad T
    Virol J; 2022 May; 19(1):92. PubMed ID: 35619180
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
    Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.
    Yao W; Shi L; Zhang Y; Dong H; Zhang Y
    Stem Cell Res Ther; 2022 Mar; 13(1):124. PubMed ID: 35321737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.
    Al-Kuraishy HM; Batiha GE; Faidah H; Al-Gareeb AI; Saad HM; Simal-Gandara J
    Inflammopharmacology; 2022 Dec; 30(6):2017-2026. PubMed ID: 36044102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
    Ting CT; Chen BS
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
    Cattel F; Giordano S; Bertiond C; Lupia T; Corcione S; Scaldaferri M; Angelone L; De Rosa FG
    Respir Physiol Neurobiol; 2021 Jun; 288():103645. PubMed ID: 33657448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoids Receptors in COVID-19: Perpetrators and Victims.
    Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Batiha GE
    Curr Med Chem; 2023; 30(34):3832-3845. PubMed ID: 36043749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
    Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
    Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
    Front Immunol; 2020; 11():588724. PubMed ID: 33117402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dehydrozingerone ameliorates Lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress via modulating the MAPK/NF-κB pathway.
    Tirunavalli SK; Gourishetti K; Kotipalli RSS; Kuncha M; Kathirvel M; Kaur R; Jerald MK; Sistla R; Andugulapati SB
    Phytomedicine; 2021 Nov; 92():153729. PubMed ID: 34517257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
    Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population.
    Torres Acosta MA; Singer BD
    Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32747391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.